Revaccination of children with acute lymphoblastic leukemia following completion of chemotherapy.
humoral immunity
leukemia
pediatrics
vaccination
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
13
02
2023
received:
25
12
2022
accepted:
05
03
2023
medline:
26
4
2023
pubmed:
11
4
2023
entrez:
10
4
2023
Statut:
ppublish
Résumé
Intensive chemotherapy for acute lymphoblastic leukemia (ALL) may affect the immune system and potentially the immune memory causing antibodies provided by vaccination to disappear. There are disagreements regarding the guidelines for posttreatment immunization strategy. Ninety-six children (aged 1-18 years at diagnosis) who completed chemotherapy for ALL were recruited. Antibody levels in the patient's serum against measles, varicella, polio, pertussis, hepatitis A, and hepatitis B were tested after completion of chemotherapy in patients who were fully vaccinated against these agents. Children who did not have positive serology to specific agents were revaccinated with a single dose accordingly. Antibody concentrations were measured again at least 4 weeks after revaccination. Positive antibody levels varied between the different agents. The highest percentage of positive serology was against polio (87%) and the lowest against pertussis (4%) (p < .001). There were significant differences between patients with high risk (HR) and non-HR ALL regarding serology status for some vaccines. After revaccination, the levels of response to each booster dose were significantly different: 100% after booster dose for varicella and polio, and only 34% after pertussis booster. Loss of humoral protection for vaccine preventable diseases is a common finding among patients with ALL. Revaccination with one dose of vaccine after completion of chemotherapy achieved seroconversion in 34-100% of the patients depending on the type of vaccine. We recommend this revaccination schedule to all children who completed ALL therapy and were previously fully vaccinated.
Sections du résumé
BACKGROUND
Intensive chemotherapy for acute lymphoblastic leukemia (ALL) may affect the immune system and potentially the immune memory causing antibodies provided by vaccination to disappear. There are disagreements regarding the guidelines for posttreatment immunization strategy.
METHODS
Ninety-six children (aged 1-18 years at diagnosis) who completed chemotherapy for ALL were recruited. Antibody levels in the patient's serum against measles, varicella, polio, pertussis, hepatitis A, and hepatitis B were tested after completion of chemotherapy in patients who were fully vaccinated against these agents. Children who did not have positive serology to specific agents were revaccinated with a single dose accordingly. Antibody concentrations were measured again at least 4 weeks after revaccination.
RESULTS
Positive antibody levels varied between the different agents. The highest percentage of positive serology was against polio (87%) and the lowest against pertussis (4%) (p < .001). There were significant differences between patients with high risk (HR) and non-HR ALL regarding serology status for some vaccines. After revaccination, the levels of response to each booster dose were significantly different: 100% after booster dose for varicella and polio, and only 34% after pertussis booster.
CONCLUSIONS
Loss of humoral protection for vaccine preventable diseases is a common finding among patients with ALL. Revaccination with one dose of vaccine after completion of chemotherapy achieved seroconversion in 34-100% of the patients depending on the type of vaccine. We recommend this revaccination schedule to all children who completed ALL therapy and were previously fully vaccinated.
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30321Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Patel SR, Ortín M, Cohen BJ, et al. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis. 2007;44(5):635-642.
Toret E, Yel SE, Suman M. Yeter Duzenli Kar, Zeynep Canan Ozdemir, Meltem Dinleyici & Ozcan Bor: immunization status and re-immunization of childhood acute lymphoblastic leukemia survivors. Hum Vaccin Immunother. 2021;17(4):1132-1135.
Crawford NW, Heath JA, Ashley D, Downie P, P Buttery J. Survivors of childhood cancer: an Australian audit of vaccination status after treatment. Pediatr Blood Cancer. 2010;54(1):128-133.
Rubin LG, Levin MJ, Ljungman P, et al. Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-318.
Royal College of Paediatrics and Child Health (RCPCH). Immunisation of the immunocompromised child-Best practice statement. 2002.
Bate J, Patel SR, Chisholm J, Heath PT. Immunization practices of paediatric oncology and shared care oncology consultants: a United Kingdom survey. Pediatr Blood Cancer. 2010;54(7):941-946. Supportive Care Group of the Children's Cancer and Leukaemia Group (CCLG).
Crawford NW, Heath JA, Ashley D, et al. Survivors of childhood cancer: an Australian audit of vaccination status after treatment. Pediatr Blood Cancer. 2010;54:128-133.
Fioredda F. Immunity against hepatitis B and measles vaccination after chemotherapy for acute lymphoblastic leukaemia in children: revaccination policy. Rev Bras Hematol Hemoter. 2012;34(4):258-259.
Koochakzadeh L, Khosravi MH, Pourakbari B, Hosseinverdi S, Aghamohammadi A, Rezaei N. Assessment of immune response following immunization with DTP/Td and MMR vaccines in children treated for acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014;31(7):656-663.
Aytac S, Yalcin SS, Cetin M, et al. Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2010;27:333-343.
Mikulska M, Cesaro S, de Lavallade H, et al. European Conference on Infections in Leukaemia groupVaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e188-e199.
Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol. 2013;1:S1-S9. Suppl.
Fayea NY, Fouda AE, Kandil SM. Immunization status in childhood cancer survivors: a hidden risk which could be prevented. Pediatr Neonatol. 2017;58(6):541-545.
Garonzi C, Balter R, Tridello G, et al. The impact of chemotherapy after pediatric malignancy on humoral immunity to vaccine-preventable diseases. Mediterr J Hematol Infect Dis. 2020;12(1):e2020014.
Cesaro S, Giacchino M, Fioredda F, et al. Guidelines on vaccinations in paediatric haematology and oncology patients. Biomed Res Int. 2014;2014:707691.
Van Tilburg CM, Sanders EA, Rovers MM, Wolfs TF, Bierings MB. Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia. 2006;20:1717-1722.
Blanc P, Liu Y, Reveneau N, Cavell B, Gorringe A, Renauld-Mongénie G. The role of bactericidal and opsonic activity in immunity against Bordetella pertussis. Expert Rev Vaccines. 2022;21(12):1727-1738.
Versteegen P, Barkoff AM, Valente Pinto M, et al. Buisman AM PERISCOPE Consortium. Memory B cell activation induced by pertussis booster vaccination in four age groups of three countries. Front Immunol. 2022;13:864674.
Keskin YZ, Buyukavci M. assessment of humoral immunity to hepatitis B, measles, rubella, and mumps in children after chemotherapy. J Pediatr Hematol Oncol. 2018;40(2):e99-e102.
Nilsson A, De Milito A, Engstrom P, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics. 2002;109(6):e91.
Fouda AE, Kandil SM, Boujettif F, Salama YS, Fayea NY. Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination. Hematology. 2018;23(9):590-595.
Lehrnbecher T, Schubert R, Allwinn R, Dogan K, Koehl U, Gruttner HP. Revaccination of children after completion of standard chemotherapy for acute lymphoblastic leukaemia: a pilot study comparing different schedules. Br J Haematol. 2011;152:754-757.